Linezolid versus vancomycin for skin and soft tissue infections

Yue, Jirong; Dong, Bi Rong; Yang, Ming; Chen, Xiaomei; Wu, Taixiang; Liu, Guan J

doi:10.1002/14651858.cd008056.pub2

Cited by 23 publications

(22 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Layer et al reported higher resistance rates in German MSSA collections as compared to the present work [ 11 ]. The detection of high MICs to vancomycin among MRSA isolates reflects the epidemiology in Greek hospitals highlighting an important therapeutic dilemma, since using vancomycin to treat infections caused by isolates with MICs ≥1.5 mg/L is associated with higher mortality as compared to newer antibiotics with anti-Gram positive action such as linezolid or daptomycin [ 13 , 14 ].…”

Section: Discussionmentioning

confidence: 99%

Spread of Tst–Positive Staphylococcus aureus Strains Belonging to ST30 Clone among Patients and Healthcare Workers in Two Intensive Care Units

Papadimitriou-Olivgeris

Δρούγκα

Fligou

et al. 2017

Toxins

View full text Add to dashboard Cite

Staphylococcus aureus is a major cause of infections. Toxic shock syndrome toxin (TSST-1) and Panton–Valentine leukocidin (PVL) are associated with severe clinical syndromes. S. aureus colonizing isolates recovered from healthcare workers and patients in the intensive care unit (ICU) of a university hospital comprising Group A were compared with those from adult non-ICU carriers (Group B). mecA, lukS/lukF-PV (Panton–Valentine leukocidin, PVL), and tst (toxic shock syndrome toxin) gene carriage was detected by PCR. Clones were identified in all methicillin-resistant S. aureus (MRSA) and toxin-positive methicillin-susceptible strains (MSSA) by pulsed-field gel electrophoresis (PFGE), agr groups, and multi locus sequencing typing (MLST). Group A included 90 S. aureus isolates, whereas Group B 53. PVL was more frequently found among MRSA vs. MSSA (p < 0.001) and in strains of Group B as compared to Group A (p < 0.001), consistent with the spread of ST80-IV. Higher incidence of tst gene carriage was identified among MSSA vs. MRSA (P 0.005) belonging mainly to ST30, and Group A vs. Group B (P 0.002). The wide dissemination of ST80-IV mainly in the community is responsible for a high percentage of PVL-positive MRSA, while silent spread of tst-positive S. aureus clones among ICU patients and personnel poses a threat of hospital transmission and possible severe infections.

show abstract

Section: Discussionmentioning

confidence: 99%

Spread of Tst–Positive Staphylococcus aureus Strains Belonging to ST30 Clone among Patients and Healthcare Workers in Two Intensive Care Units

Papadimitriou-Olivgeris

Δρούγκα

Fligou

et al. 2017

Toxins

View full text Add to dashboard Cite

show abstract

“…Increased resistance to glycopeptides has encouraged the development of new agents active against Gram-positive bacteria, particularly for severe soft tissue infections where an aggressive antimicrobial management is always recommended, such as linezolid [ 53 – 55 ], tigecycline [ 56 , 57 ] and daptomycin [ 58 , 59 ].…”

Section: Executive Summarymentioning

confidence: 99%

“…Recently a Cochrane meta-analysis including all randomised controlled trials (RCTs) comparing linezolid with vancomycin in the treatment of SSTIs [ 55 ].…”

Section: Executive Summarymentioning

confidence: 99%

See 1 more Smart Citation

World Society of Emergency Surgery (WSES) guidelines for management of skin and soft tissue infections

et al. 2014

View full text Add to dashboard Cite

Skin and soft tissue infections (SSTIs) encompass a variety of pathological conditions ranging from simple superficial infections to severe necrotizing soft tissue infections. Necrotizing soft tissue infections (NSTIs) are potentially life-threatening infections of any layer of the soft tissue compartment associated with widespread necrosis and systemic toxicity. Successful management of NSTIs involves prompt recognition, timely surgical debridement or drainage, resuscitation and appropriate antibiotic therapy. A worldwide international panel of experts developed evidence-based guidelines for management of soft tissue infections. The multifaceted nature of these infections has led to a collaboration among surgeons, intensive care and infectious diseases specialists, who have shared these guidelines, implementing clinical practice recommendations.

show abstract

“… 2 However, its serious side effects that occur when the course of treatment exceeds 28 days, limit its clinical use. 7 Further research is required to determine whether other drugs, including daptomycin, are more efficacious than the recommended standard therapy.…”

Section: Introductionmentioning

confidence: 99%

Efficacy and safety of daptomycin for skin and soft tissue infections: a systematic review with trial sequential analysis

Liu

Mao

Kang

et al. 2016

TCRM

View full text Add to dashboard Cite

BackgroundSkin and soft tissue infections (SSTIs) are significant indications for antibiotic treatment. Daptomycin, a novel antibiotic, has been registered and licensed to be used in the treatment of these infections. However, its efficacy and safety remain controversial.ObjectiveThe objective of this study was to conduct a systematic review with trial sequential analysis (TSA) to evaluate the efficacy and safety of daptomycin for the treatment of SSTIs and to analyze whether the available sample size has been large enough and is conclusive.MethodsPubMed, the Cochrane Library, and EMBASE were searched for published randomized controlled trials (RCTs) that compared daptomycin with other antibiotics in adult patients with SSTIs up to February 2016.ResultsThis meta-analysis included eight randomized controlled trials (n=2,002). There was no difference in either the clinical success rate (intention-to-treat population: relative risk [RR] =1.04, 95% confidence interval [CI] =0.99–1.10, P=0.12; clinically evaluable population: RR =1.00, 95% CI =0.97–1.04, P=0.82) or the microbiological success rate (RR =1.00, 95% CI =0.95–1.06, P=0.92) between the daptomycin and comparator groups for treating SSTIs, which was confirmed by TSA. Compared with vancomycin, daptomycin exhibited no advantage in increasing the clinical success rate (RR =1.03, 95% CI =0.95–1.13, P=0.47), and this was also confirmed by TSA. All-cause mortality, overall treatment-related adverse events, and creatine phosphokinase events were similar between these two groups.ConclusionDaptomycin and comparator drugs are equally efficacious with regard to clinical and microbiological success for patients with SSTIs, and TSA showed that no additional randomized controlled trials are required. Although daptomycin is a good alternative when other antibiotics are contraindicated for patients with SSTIs and it can serve as a first-line treatment for SSTIs, clinicians should be aware of potential adverse events, such as daptomycin-induced acute eosinophilic pneumonia and creatine phosphokinase, when treating patients with daptomycin.

show abstract

Linezolid versus vancomycin for skin and soft tissue infections

Cited by 23 publications

References 50 publications

Spread of Tst–Positive Staphylococcus aureus Strains Belonging to ST30 Clone among Patients and Healthcare Workers in Two Intensive Care Units

Spread of Tst–Positive Staphylococcus aureus Strains Belonging to ST30 Clone among Patients and Healthcare Workers in Two Intensive Care Units

World Society of Emergency Surgery (WSES) guidelines for management of skin and soft tissue infections

Efficacy and safety of daptomycin for skin and soft tissue infections: a systematic review with trial sequential analysis

Contact Info

Product

Resources

About